NEWM&A

Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders

Published on 3/31/2026

#LLY#M&A#OX2R#Centessa
Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders

AI Summary

Lilly (LLY) announced the acquisition of Centessa Pharmaceuticals, focusing on OX2R drug candidates for sleep disorders. This strategic move aims to enhance LLY's portfolio in the sleep medicine market, which has seen increasing demand. Financial terms of the deal were not disclosed, but the acquisition is anticipated to bolster LLY's research and development capabilities. The market impact could reflect positively on LLY's stock as they expand their therapeutic offerings.

Source: Read original article (opens in new tab)

Related News

Strawberry Fields REIT (SFR) Director Buys $17,465 in Stock
M&A

Strawberry Fields REIT (SFR) Director Buys $17,465 in Stock

Mar 31

Stocks Soar on Hopes of Iran War Resolution Amid Market Optimism
Markets

Stocks Soar on Hopes of Iran War Resolution Amid Market Optimism

Mar 31

Japan Post Holdings (JPST) sells Aflac shares for $1.55 million
M&A

Japan Post Holdings (JPST) sells Aflac shares for $1.55 million

Mar 31

Centessa (CNTA) Downgraded After Lilly Deal Announcement
Markets

Centessa (CNTA) Downgraded After Lilly Deal Announcement

Mar 31